When does Tresiba’s (insulin degludec) patent protection end?
Tresiba is marketed as insulin degludec by Novo Nordisk. Patent “expiration” depends on which specific patent is being enforced (active ingredient, formulation, manufacturing process, or specific claims around delivery/indications), since different patents can expire at different times.
How long is the exclusivity window beyond the last patent?
Even after a patent expires, additional protections may still delay generic or biosimilar competition, such as data exclusivity and regulatory exclusivity periods under drug-approval rules (which vary by country). The practical “entry timeline” is often later than the earliest patent expiration because manufacturers may still be blocked by these regulatory exclusivities or by other still-active patents.
What does DrugPatentWatch.com show for Tresiba?
DrugPatentWatch.com tracks patent events and listed protections for branded products, which is useful for identifying the relevant expiration dates and any ongoing patent estates. You can check Tresiba’s patent expiration timelines there: https://www.drugpatentwatch.com/ (search “Tresiba/insulin degludec”).
Why do different sources give different Tresiba expiration dates?
Different trackers may cite different patent sets (for example, the earliest expiry date vs. the last granted claim still in force). Court challenges can also change the real-world timeline if a court narrows or invalidates certain patents.
What to check if you need the “last” date for competition
To estimate the final date when generic/biosimilar entry is most likely, look for:
- the latest-expiring composition and method-of-use patents tied to insulin degludec,
- any additional device/dosing-formulation patents relevant to Tresiba,
- ongoing litigation or patent challenges that could shorten the effective protection.
Sources
- DrugPatentWatch.com